Education
About Us
Working with TipRanks
Follow Us
Sprint Bioscience AB (SE:SPRINT)
:SPRINT
RESEARCH TOOLSreports
Top Page
Sprint Bioscience AB
(Frankfurt:SPRINT)
44Neutral
Sprint Bioscience AB (SPRINT) vs. S&P 500 (SPY)
Market Cap
€77.76M
Dividend YieldN/A
Average Volume (3M)114.50K
Price to Earnings (P/E)―
Beta (1Y)0.49
Revenue Growth30.02%
EPS Growth-3985.71%
CountrySE
Employees34
SectorHealthcare
Sector Strength65
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding117,821,400
10 Day Avg. Volume109,082
30 Day Avg. Volume114,504
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Sprint Bioscience AB Business Overview & Revenue Model
Company DescriptionSprint Bioscience AB (SPRINT) is a biotechnology company based in Sweden, specializing in the early-stage development of oncology therapeutics. The company focuses on the discovery and development of innovative small-molecule drug candidates targeting cancer metabolism and tumor immune evasion. Their leading programs are aimed at addressing unmet medical needs in cancer treatment by advancing proprietary projects through preclinical phases, with the ultimate goal of out-licensing them to pharmaceutical partners for further development and commercialization.
How the Company Makes MoneySprint Bioscience generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical companies. By advancing its drug candidates to a preclinical stage, the company positions itself to enter partnerships where it grants rights to its drug candidates in exchange for upfront payments, milestone payments, and royalties on future sales. These partnerships allow Sprint Bioscience to leverage the resources and expertise of established pharma companies to bring its innovations to market. Additionally, the company may receive government grants or research funding to support its development projects, although these are not its primary revenue streams.
Sprint Bioscience AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 65.64M | 50.48M | 83.00K | 35.11M | 16.89M | Gross Profit |
| 37.30M | 41.79M | -60.91M | 24.68M | 6.43M | EBIT |
| -19.67M | -845.00K | -60.91M | -25.47M | -37.67M | EBITDA |
| -17.28M | -2.08M | -60.00M | -24.49M | -38.05M | Net Income Common Stockholders |
| -18.28M | -438.00K | -60.17M | -25.35M | -46.23M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 25.06M | 49.93M | 29.49M | 70.64M | 27.07M | Total Assets |
| 42.05M | 62.38M | 37.42M | 79.14M | 33.40M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 10.00M | Net Debt |
| -25.06M | -49.93M | -29.49M | -70.64M | -17.07M | Total Liabilities |
| 32.78M | 34.60M | 9.23M | 8.68M | 24.25M | Stockholders Equity |
| 9.27M | 27.77M | 28.19M | 70.45M | 9.14M |
| Cash Flow | Free Cash Flow | |||
| -24.65M | 20.42M | -59.05M | -42.82M | -32.22M | Operating Cash Flow |
| -23.36M | 22.87M | -59.05M | -40.12M | -32.22M | Investing Cash Flow |
| -1.30M | -2.45M | 0.00 | -2.71M | 0.00 | Financing Cash Flow |
| -225.00K | 24.00K | 17.90M | 86.39M | 50.92M |
Sprint Bioscience AB Technical Analysis
Negative
0.66
Price Trends
1.04
Negative
1.32
Negative
1.38
Negative
Market Momentum
-0.10
Negative
32.70
Neutral
68.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPRINT, the sentiment is Negative. The current price of 0.66 is below the 20-day moving average (MA) of 0.67, below the 50-day MA of 1.04, and below the 200-day MA of 1.38, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 32.70 is Neutral, neither overbought nor oversold. The STOCH value of 68.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SPRINT.
Sprint Bioscience AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.31B | 3.33 | -39.82% | 2.92% | 17.95% | 1.84% | |
49 Neutral | kr46.73M | ― | -47.01% | ― | -94.12% | -25.83% | |
44 Neutral | €77.76M | ― | -96.58% | ― | 30.02% | -3985.71% | |
40 Underperform | kr51.57M | ― | -55.51% | ― | -57.26% | 72.71% | |
36 Underperform | kr71.73M | ― | -85.93% | ― | 58.72% | 70.69% | |
35 Underperform | kr46.00M | ― | -152.99% | ― | ― | 58.36% | |
33 Underperform | €25.24M | ― | -104.30% | ― | ― | 63.82% |
* Healthcare Sector Average
Performance Comparison
SE:SPRINT
Sprint Bioscience AB
0.67
-0.60
-47.48%
SE:COMBI
CombiGene AB
2.41
-1.36
-36.07%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
19.40
-74.26
-79.29%
SE:MODTX
Modus Therapeutics Holding AB
1.28
0.31
32.23%
SE:SPAGO
Spago Nanomedical AB
0.22
-0.14
-39.17%
SE:STABL
Stayble Therapeutics AB
0.46
0.23
97.42%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.